Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 18.1% in February

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 98,894 shares, a drop of 18.1% from the January 29th total of 120,679 shares. Based on an average daily trading volume, of 74,849 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 74,849 shares, the days-to-cover ratio is presently 1.3 days.

Lixte Biotechnology Price Performance

LIXT traded down $0.04 during trading on Wednesday, hitting $2.81. The company had a trading volume of 9,500 shares, compared to its average volume of 47,919. Lixte Biotechnology has a 1-year low of $0.64 and a 1-year high of $6.26. The company has a market cap of $21.02 million, a PE ratio of -2.38 and a beta of 0.86. The business has a 50-day moving average of $3.35 and a 200-day moving average of $4.06.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lixte Biotechnology has an average rating of “Sell”.

Hedge Funds Weigh In On Lixte Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the business. DRW Securities LLC increased its stake in Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after buying an additional 10,722 shares during the period. Axxcess Wealth Management LLC bought a new stake in shares of Lixte Biotechnology during the 4th quarter valued at about $54,000. XTX Topco Ltd acquired a new stake in Lixte Biotechnology during the fourth quarter worth about $57,000. Finally, Renaissance Technologies LLC raised its stake in Lixte Biotechnology by 47.0% during the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after acquiring an additional 34,350 shares during the period. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.